JAGSONPAL PHARMACEUTICALS LTD.

Jagsonpal Pharmaceuticals Ltd announced the designation of two new Senior Management Personnel: Mr. Balmukund Keshav as Deputy General Manager (Information Technology) and Mr. Sanjay Singhal as General Manager (CQA & Regulatory Affairs). These appointments are effective July 29, 2026, following an internal restructuring. Mr. Keshav brings over 29 years of IT leadership experience, while Mr. Singhal has 31 years of experience in the pharmaceutical industry, with expertise in manufacturing, supply chain, quality, and regulatory affairs. The company has provided detailed profiles and disclosures as per SEBI regulations.

Jagsonpal Pharmaceuticals Ltd has announced September 04, 2026, as the record date for determining shareholder entitlement to a proposed dividend of ₹4 per equity share (200%) for the financial year ended March 31, 2026. The dividend recommendation was made by the Board of Directors on April 27, 2026, and is subject to shareholder approval at the 47th Annual General Meeting (AGM) scheduled for September 18, 2026. The AGM will be conducted via Video Conferencing. If approved, the dividend will be paid within 30 days of declaration, after deducting applicable taxes.

Jagsonpal Pharmaceuticals announced its Q1 FY27 results, reporting a strong start to the fiscal year. Revenue increased by 9% year-on-year to ₹822 Mn, while Profit After Tax (PAT) saw a significant jump of 22% to ₹132 Mn. Operating EBITDA also grew by 21% YoY to ₹191 Mn, with margins expanding by 241 bps to 23.2%. The company maintained robust liquidity with cash reserves of ₹1,700 Mn, even after a ₹400 Mn share buyback. The acquisition of Aequitas Healthcare was completed, marking the company's entry into the hospital business segment, with a target of ₹100+ Mn EBITDA from Aequitas within two years post-integration. The company's market share improved, ranking #88 in the Indian pharmaceutical market.

Jagsonpal Pharmaceuticals Ltd announced its unaudited financial results for the first quarter ended June 30, 2026. The company's total income for the quarter stood at ₹850.65 million, a notable increase from ₹673.71 million in the previous quarter (March 31, 2026). Revenue from operations was ₹822.32 million. The Board of Directors approved these results in a meeting held on July 29, 2026. The Limited Review Report was issued by statutory auditors Walker Chandiok & Co LLP, who found no material misstatements.

Jagsonpal Pharmaceuticals Limited announced the outcome of its Board Meeting held on July 29, 2026, which included the declaration of Unaudited Standalone Financial Results for the quarter ended June 30, 2026 (Q1 FY27). The results were prepared in accordance with Indian Accounting Standard 34 and reviewed by statutory auditors Walker Chandiok & Co LLP. The board meeting commenced at 3:45 p.m. and concluded at 4:17 p.m.

Jagsonpal Pharmaceuticals Ltd has announced that its Board of Directors will convene on July 29, 2026. The primary agenda item for this meeting is to consider and approve the unaudited financial results for the first quarter ended June 30, 2026. Additionally, the company confirmed that the trading window for its securities will remain closed until July 31, 2026, as previously intimated on June 26, 2026. This announcement is made in compliance with SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015.

Jagsonpal Pharmaceuticals Ltd has announced the successful completion of its acquisition of an 85% equity stake in Aequitas Healthcare Private Limited. This follows previous intimations regarding the proposed acquisition dated June 29, 2026, and further updates on July 7 and July 8, 2026. The company has formally informed the stock exchange of this development and requested it be taken on record. This strategic move is expected to bolster Jagsonpal Pharmaceuticals' presence and capabilities within the healthcare sector.

Jagsonpal Pharmaceuticals Ltd has announced the completion of its acquisition of a 77.21% equity stake in Aequitas Healthcare Private Limited. This follows previous disclosures on June 29, 2026, and July 7, 2026, regarding the proposed acquisition. The company had initially aimed to acquire an 85% stake. This development signifies a significant step in Jagsonpal's strategic growth and expansion within the healthcare sector.

Jagsonpal Pharmaceuticals Limited has announced the completion of the acquisition of 69.77% of the equity stake in Aequitas Healthcare Private Limited. This transaction, initially proposed for an 85% stake, has now resulted in Aequitas Healthcare becoming a subsidiary of Jagsonpal Pharmaceuticals. The company has informed the stock exchanges of this significant development, marking a strategic move to expand its operations and market presence through this acquisition.

Jagsonpal Pharmaceuticals Ltd. has entered into a definitive agreement to acquire an 85% equity stake in Aequitas Healthcare Private Limited for ₹20.8 crores. This strategic acquisition marks Jagsonpal's entry into the hospital segment, aiming to strengthen its presence in India's healthcare ecosystem. Aequitas, founded in 2017, focuses on the sale and distribution of pharmaceutical products to hospitals and reported revenues of ₹53 crores in FY26. The transaction, funded by internal accruals, is expected to conclude by July 15, 2026. This move is seen as a transformative pivot for Jagsonpal, shifting from a legacy retail prescription player to an omnichannel specialty healthcare business.